The MS assay optimized in our laboratory is able to reveal LOH at 1p/19q chromosome arms and the presence of hotspot mutations in IDH1, IDH2, and TERT. It was optimized and validated by the analysis of 50 glioma samples, as detailed below. This evidence concerns the gene IDH2 and central nervous system cancer.